In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.
Trials
- Atogepant (AGN-241689)
- Erenumab (AMG 334)
- Galcanezumab (LY2951742)
- Fremanezumab (TEV-48125)
- Eptinezumab (ALD403)
- Rimegepant (BHV-3000)
- Ubrogepant (MK-1602)
Meeting Reports
- Migraine Trust International Symposium 2020
- 14th European Headache Federation Congress
- 62nd Annual Meeting of the American Headache Society
- 6th Congress of the European Academy of Neurology
- American Academy of Neurology 2020
- World Congress of Neurology 2019
- IHC 2019
- American Headache Society (AHS) 61st Annual Scientific Meeting
- 5th Congress of the European Academy of Neurology
- 13th European Headache Federation Congress
- American Academy of Neurology Annual Meeting 2019
- 12th European Headache Federation Congress
- 17th Biennial Migraine Trust International Symposium
- American Headache Society (AHS) 60th Annual Scientific Meeting
- 4th Congress of the European Academy of Neurology
- American Academy of Neurology (AAN) Congress
- 11th European Headache Federation Congress
- 18th Congress of the International Headache Society
- American Headache Society Annual Scientific Meeting
- 3rd Congress of the European Academy of Neurology
- American Academy of Neurology Annual Meeting
- Scottsdale Headache Symposium
- The European Headache and Migraine Trust International Congress (EHMTIC)